

For Immediate Release

June 4, 2018

**CNRP ANNOUNCES ACQUISITION OF X-SPRAYS
AND WARRANT EXTENSION**

CNRP Mining Inc. (“**CNRP**” or the “**Company**”) (**CSE: CND**)(**OTCQB: CRPGF**) is pleased to announce that further to its press release of October 25, 2017 it has completed the acquisition (the “**Transaction**”) of all of the issued and outstanding shares of 1127466 B.C. Ltd. (“**X-SPRAYS**”), which holds, through a wholly-owned subsidiary, a world-wide, exclusive license for X-SPRAYS™ – a brand of state-of-the-art life-enhancement products administered via an optimal oral spray delivery system, a private British Columbia company, pursuant to the terms of a share exchange agreement dated October 24, 2017, as amended, (the “**Share Exchange Agreement**”). The Transaction constitutes a “fundamental change” for the Company pursuant to the policies of the Canadian Securities Exchange (the “**CSE**”).

In consideration for the Transaction, the Company issued 16,500,000 common shares in the capital of CNRP (the “**Payment Shares**”) to the holders of X-SPRAYS securities at a deemed price of \$0.30 per Payment Share. In addition, up to 28,000,000 CNRP shares will be issuable upon certain commercial milestones being achieved by X-SPRAYS.

In connection with the Transaction, the Company also issued 1,650,000 common shares to an arm’s length third party at a deemed price of \$0.30 per Common Share as a finder’s fee.

The Company has received conditional approval of the Acquisition from the CSE. Trading on the CSE under the symbol “ICAN” is expected to resume once final approval is obtained from the CSE.

For further details on the Acquisition please see the Listing Statement of the Company dated May 18, 2018 which was filed under the Company’s profile at www.sedar.com.

The Company is also pleased to announce that with the approval of the CSE, it has approved an extension of the expiry date of 2,798,955 outstanding common share purchase warrants (the “**Warrants**”), which were issued pursuant to a private placement that closed on June 13, 2017 (the “**Warrant Amendment**”). The Warrant Amendment will be effective as of June 6, 2018. Each Warrant currently entitles the holder to purchase one common share in the capital of the Company at a price of \$0.30 per share until June 13, 2018. Pursuant to the Warrant Amendment, the expiry date of the Warrants has been extended from June 13, 2018 to June 13, 2019. All other terms of the Warrants will remain the same.

None of the securities issued pursuant to the Transaction have been or will be registered under the U.S. Securities Act of 1933, as amended (the “U.S. Securities Act”), or any state securities laws, and any securities issued pursuant to the Transaction were issued in reliance upon available exemptions from such registration requirements pursuant to Rule 506(b) of Regulation D and/or Section 4(a)(2) of the U.S. Securities Act and applicable exemptions under state securities laws. In addition, the securities issued under an exemption from the registration requirements of the U.S. Securities Act are “restricted securities” as defined under Rule 144(a)(3) of the U.S. Securities Act and contain the appropriate restrictive legend as required under the U.S. Securities Act.

About X-SPRAYS™

X-SPRAYS™ is comprised of dedicated scientists and product engineers who are passionate about health and creating the ultimate delivery system for optimal nutrition. The company has focused its efforts in creating a product line of oral sprays to deliver medicines, nutrients and vitamins. To date, X-SPRAYS™ has developed a novel line of 8 health care and life-enhancement nutraceutical products focused on enhancing pain relief, awareness, sleep, libido, energy and recovery.

The Company’s product line is ready for commercialization with 8 novel sprays that include both hemp cannabidiol (CBD) and nutraceutical ingredients (4 with CBD and 4 nutraceutical). X-SPRAYS™ intends to expand its product line to include cannabis Tetrahydrocannabinol (THC) and CBD sprays. For more information, please visit the company’s website at: www.x-sprays.com.

ON BEHALF OF THE BOARD OF DIRECTORS

“John S Knapp”

John S. Knapp
CEO and Director

The CSE does not accept responsibility for the adequacy or accuracy of this release.

Cautionary Statement Regarding “Forward-Looking” Information

This information release contains certain forward-looking information. Such information involves known and unknown risks, uncertainties and other factors that may cause actual results, performance or achievements to be materially different from those implied by statements herein, and therefore these statements should not be read as guarantees of future performance or results. All forward-looking statements are based on the Company's current beliefs as well as assumptions made by and information currently available to it as well as other factors. Readers are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date of this press release. Due to risks and uncertainties, including the risks and uncertainties identified by the Company in its public securities filings, actual events may differ materially from current expectations. The Company disclaims any intention or obligation to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise.